Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zoetis (NY:ZTS)

120.49 +0.41 (+0.34%)
Streaming Delayed Price Updated: 10:37 AM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zoetis

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
News headline image
Jim Cramer Recommends Not Buying Mosaic, Doesn't Like This Industrial Stock ↗
 
Via Benzinga
News headline image
A Look Into Zoetis Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
ZTS Q1 Earnings Call: Guidance Raised as Platform Products Drive Momentum Amid Competitive Pressures
Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance... 
Via StockStory
Topics Economy World Trade
News headline image
3 Profitable Stocks to Research Further
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline. 
Via StockStory
News headline image
How Do Investors Really Feel About Zoetis? ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
P/E Ratio Insights for Zoetis ↗
 
Via Benzinga
News headline image
Looking Into Zoetis's Recent Short Interest ↗
 
Via Benzinga
News headline image
Zoetis to Participate in Upcoming Investor Conferences
From Zoetis Inc.
Via Business Wire
News headline image
Here's How Much $100 Invested In Zoetis 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Zoetis Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
Zoetis Beats Wall Street Estimates, Revises 2025 Guidance To Include Tariffs Impact ↗
Zoetis beats Q1 estimates with $1.48 EPS and $2.22 billion revenue, raises full-year forecast on strong demand for companion animal health products. 
Via Benzinga
News headline image
Which S&P500 stocks are gapping on Tuesday? ↗
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday? ↗
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting. 
Via Benzinga
Topics Economy
News headline image
Zoetis’s (NYSE:ZTS) Q1: Beats On Revenue, Full-Year Sales Guidance is Optimistic
Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance... 
Via StockStory
News headline image
Zoetis Announces First Quarter 2025 Results
From Zoetis Inc.
Via Business Wire
News headline image
Zoetis (ZTS) Q1 Earnings: What To Expect
Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results tomorrow before market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Safe-and-Steady Stock to Target This Week and 2 to Be Wary Of
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off ↗
Via The Motley Fool
Topics Economy Intellectual Property World Trade
News headline image
1 Superstar Dividend Growth Stock to Buy if the Market Crashes ↗
Investors have been waiting nearly a decade to score a good deal on this healthcare star. 
Via The Motley Fool
Topics Economy Government
News headline image
A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now ↗
Via The Motley Fool
News headline image
3 Magnificent Stocks to Buy That Are Near 52-Week Lows ↗
Via The Motley Fool
Topics Economy Government
News headline image
2 of Wall Street’s Favorite Stocks with Competitive Advantages and 1 to Be Wary Of
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
This Magnificent Dividend Stock Has Increased Its Payouts by 500% in 10 Years ↗
Via The Motley Fool
News headline image
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy. ↗
Via The Motley Fool
News headline image
Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results
From Zoetis Inc.
Via Business Wire
News headline image
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.